Daniel Kluttz

Alta Charo, emerita professor of law and bioethics, shares her expertise in biotechnology policy, focusing on the regulatory landscape of genome editing. She discusses the importance of differentiating hazards from risks in biotechnological advances. Daniel Kluttz from Microsoft dives into how lessons from genome editing can shape AI governance. The conversation emphasizes the need for ethical frameworks and international coordination in both fields, ensuring a responsible balance between innovation and oversight.